

Annual Report
Division of Gastroenterology
Department of Medicine - Jewish General Hospital
January 1 - December 31, 2012

SUMMARY:

Introduction

The Division of Gastroenterology continues to strive to strike a healthy balance between providing services to the ever growing demands imposed upon us and achieving academic excellence

Clinical Activities

Office visits

Dr. A. Cohen	Monday to Friday	8-4 pm	
Dr. G. Friedman	Monday to Friday	8-4 pm	21 700 visits/year
Dr. A. Szilagyi	Monday to Friday	8-4 pm	
Dr. N. Hilzenrat	Monday to Friday	8-4 pm	
Dr. P. Galiatsatos	Monday to Friday	8-4 pm	

Addendum to office visits.

The total number of visits continues to grow and this is purely a result of patients going through the emergency room to obtain access to specialized services such as gastroenterology.

Endoscopy laboratory: our volume has decreased to 7187 procedures/year since 2009 (9000 procedures) and 2010 (8771 procedures). This is the result of increased demands in terms of nursing care to comply with conscious sedation guidelines and no commensurate increase in the number of nurses in endoscopy. Without an increase in resources, we expect our volume of endoscopic procedures to drop even further in 2011-2012. This is having a very grave impact on our already engorged waiting lists.

Monday to Friday 8-4 pm 7165 procedures/year

Cholangiopancreatography (ERCP)

Mondays and Thursdays 1-4 pm 295 procedures/year (included in Endoscopy)

Anemia Clinic: Cancelled due to shortage of nurses.

Inflammatory Bowel Disease Clinics

Monday to Friday 8-12 pm 3500 visits/year (included in office visits)

Clinical trials in inflammatory bowel disease have continued to flourish. We are participating in numerous international clinical trials under the direction of our research nurse, Stefania D'Aleo.

Hepatology clinic

Dr. N. Hilzenrat
Monday to Friday

8-4 pm

5202 visits/year
(included in office visits)

Maria Stavrakis and Paul Plaisir are our research nurses in Hepatology. Activities include conduction of clinical trails in Hepatology as well as teaching and monitoring of patients undergoing anti-viral therapy for chronic hepatitis.

GI Service

In-patient activities revolve around the GI consulting service which is attended by our staff physician on a two week rotating schedule throughout the year. The volume of consultations is approximately 2400/year, the majority of which involve endoscopic procedures.

1. Research activities:

Dr. Albert Cohen

GSK in Crohn's (CCX114644): A Randomised, Double-blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects with Moderately to Severely Active Crohn's Disease: Glaxo Smith Kline/CRO: Robarts

GSK in Crohn's Disease (CCX114157): Phase III Study-A 52 Week Randomised, Double-blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of GSK1605786A in the Maintenance of Remission in Subjects with Crohn's disease. Glaxo Smith Kline/CRO: Robarts

GSK in Crohn's Disease (CCX114151): Phase III Study, A Randomised, Double-blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects with Moderately to Severely Active Crohn's Disease. Glaxo Smith Kline/CRO: Robarts

MLN0002 In Crohn's (13007): A Phase 3, Randomized, Placebo Controlled, Blinded, Multicenter Study of the Induction and Maintenance of Clinical Response and Remission by MLN0002 in Patients with Moderate to Severe Crohn's Disease. Quintiles/CRO PRA Int.

MLN0002 in Crohn's (C13006): A Phase 3, Randomized, Placebo-Controlled, Blinded, Multicentre Study of the Induction and Maintenance of Clinical Response and Remission by MLN0002 in Patients with Moderate to Severe Ulcerative Colitis.

MLN0002 in UC and Crohn's (C13008)

Extension Study An Open-Label Phase 3 Study: An Open-Label 3 Study to determine the long-term efficacy and safety of MLN0002 in Patients with Ulcerative Colitis and Crohn's Disease. (Quintiles/CRO PRA Int)

IN UC and Crohn's (CI C0168T62: A Multi-centre International Study of the Long-Term Safety of Infliximab (Remicade) in ulcerative colitis. Advanced Biologics/PRA International-CRO

Open-label Adalimumab S/C in Ulcerative Colitis

Extension study of placebo controlled trial. Multicenter International Trial

Site Principal Investigator; Sponsor: Abbott Laboratories

Quebec Genetic Consortium- Identification of the genes responsible for inflammatory bowel disease. This study represents collaboration between gastroenterologists throughout Quebec, involving all medical faculties in conjunction with the Whitehead Institute and the National Health Institute, Bethesda, MD. Multicenter International trial

Site Principal Investigator; Co-investigator: Dr. A. Szilagyi, Dr. G. Friedman, Dr. S. Blum, Dr. N. Hilzenrat; 2003 to present

Dr. Nir Hilzenrat

Is HCV genotype 3 associated with type 2 diabetes? Site principal investigator: Hilzenrat Nir; Co-investigator: Kader T; Funding: Jewish General Hospital GI, Research Group; 2008-date

The role of different biological systems in the etiology of interferon alpha induced depression.

Principal Investigator: Marie-Josée Brouillette

Site principal investigator: Hilzenrat Nir; Co-investigator: Deschenes M

Funding: CHIR- Canadian Institutes of Health Research. 2008-2013

Short term memory defect in HCV patients treated with Interferon.

Site principal investigator: Hilzenrat Nir; Funding: Jewish General Hospital, GI Research Group; 2011-date

A Phase 3 Study with Asunaprevir and Daclatasvir (DUAL) for Null or Partial Responders to Peginterferon Alfa and Ribavirin (P/R), Intolerant or Ineligible to P/R Subjects and Treatment-Naïve Subjects with Chronic Hepatitis C Genotype 1b Infection

Site principal investigator: Hilzenrat Nir; Sponsor: Bristol-Myers Squibb Research and Development; 2012-date

Short Term Memory Defect in Hepatitis C Patients Treated with Interferon, Department of Medicine, JGH

Dr. Jonathan Wyse

The value of Botox-A in Acute Radiation Proctitis, Department of Medicine, JGH

2. Teaching and learning (undergraduate and graduate):

Total clinical teaching hours

Dr. S. Blum, Dr. A. Cohen, Dr. G. Friedman, Dr. N. Hilzenrat Dr. A. Szilagyi, Dr. J. Wyse, Dr. P. Galiatsatos	Gastroenterology consult service	300 hrs/yr. for each physician
---	-------------------------------------	--------------------------------------

Post-graduate teaching hours

GI Pathology Conference Wednesdays 8-9 am (alternate week)
Dr. A. Gologan & Dr. Olga Aleynikova

GI Radiology Conference Wednesdays 8-9 am (alternate week)
Dr. M. Rosenbloom

GI Journal Club, M&M rounds Wednesdays 8-9 am, once/month

McGill interhospital GI rounds Wednesdays 5-6 pm

MED 1:

McGill Gastrointestinal Physiology Small Group Tutor, Unit IV: Dr. A. Cohen, Dr. G. Friedman, Dr. N. Hilzenrat, Dr. P. Galiatsatos, Dr. J. Wyse and Dr. A. Szilagyi – total number of hours: 16/physician

Total Clinical Teaching hours:

Residents: CTU: 80 hours OPD: 800

Students: CTU: 80 hours OPD: 200

- 3. Involvement in the community:** None to report.
- 4. Partnerships:** None to report.
- 5. Milestones: New hires, promotions, and retirements:** None to report.
- 6. Honours, awards, and prizes:** None to report in 2012
- 7. Fundraising:** None to report.

SECTION I - DIVISION STATUS UPDATE

1. Mission and objectives of the Division

The objectives of the Division of Gastroenterology remain:

The objectives of the division of Gastroenterology remain academic excellence while providing good service to the hospital and to the community. Our research priorities will continue to revolve around novel therapies for viral hepatitis, non-invasive assessment of liver cirrhosis, develop our

understanding of intestinal microbes and their role in health and disease, and of course, optimizing care of our patients suffering from inflammatory bowel diseases.

2. A nominative list of academic staff, their academic rank

Full-time (GFT) members:

Dr. Albert Cohen, Director of Division of Gastroenterology, Associate Professor, McGill University

Dr. Nir Hilzenrat, Gastroenterologist and Hepatologist, Associate Professor, McGill University

Dr. Gad Friedman, Gastroenterologist, Assistant Professor, McGill University

Dr. Polymnia Galiatsatos, Gastroenterologist, Assistant Professor, McGill University

Dr. Jonathan Wyse, Gastroenterologist, Assistant Professor, McGill University

Dr. Andrew Szilagyi, Gastroenterologist, Assistant Professor, McGill University

SECTION II - GRANTS, PUBLICATIONS, AND SERVICE OUTSIDE OF MCGILL

1. Grants and Awards – listed under Research

2. Publications

Galiatsatos, Polymnia

-- Al-Zafiri R, Gologan A, **Galiatsatos P, Szilagyi A**. Cytomegalovirus complicating inflammatory bowel disease: A 10-year experience in a community-based, university – affiliated hospital, *Gastroenterol Hepatol* 2012; 8: 230-39.

Hilzenrat, Nir

--Amson M, Lamoureux E, **Hilzenrat N**, Tischkowitz M. Alagille Syndrome and Wilson Disease in Siblings: Interrelated or Coincidental? *Canadian Journal of Gastroenterology* 2012;26:330-332.

--Lee S.S, Sherman M, Ramji A, Greenbloom S, Elkashab M, Pluta H, **Hilzenrat N**, Balshaw N, Usaty C, Myers R.P. Randomised clinical trial: the efficacy of treatment, guided by a shorter duration of response, using peginterferon alfa-2a plus ribavirin for hepatitis C virus other than genotypes 2 or 3. has been accepted for publication in *Alimentary Pharmacology & Therapeutics* 2012; 35: 37-47.

--Neuman M, Schmilovitz-Weiss H, **Hilzenrat N**, Bourlière M, Marcellin P, Trepo C, Mazulli T, Moussa G, Patel A, Baig AA and Cohen L. Markers of inflammation and fibrosis in alcoholic hepatitis and viral hepatitis C. *International Journal of Hepatology* 2012. doi: 10.1155/2012/231210.

-- Lazarus D, Albusafi S, **Hilzenrat N**. Chylous ascites secondary to giant liver hemangioma: Case report and review of literature. *Case Report In Gastroenterology*. Manuscript No.: 201204012.

-- Al-Busafi S, McNabb-Baltar J, Farag A, **Hilzenrat N**. Clinical Manifestations of Portal Hypertension. *International Journal of Hepatology*, vol. 2012. Article ID 203794, 10 pages, 2012. doi:10.1155/2012/203794.(<http://www.hindawi.com/journals/ijhep/contents/> or <http://www.hindawi.com/journals/ijhep/2012/203794/>)

-- **Hilzenrat N** and Sherker A. Esophageal varices: pathophysiology, approach, and clinical dilemmas, *International Journal of Hepatology*, vol. 2012, Article ID 795063, 2 pages, 2012. doi:10.1155/2012/795063.

--Neuman M, Winkler RE, **Hilzenrat N**, Cohen L, Nanau RM. Multiple factors involved in nonalcoholic hepatitis pathogenesis. *International Journal of Hepatology* 2012, Article ID 429805, 2 pages, 2012. doi:10.1155/2012/429805.

--**Hilzenrat N**, Lamoureux E, Szilagyi A. Fatty Liver Disease. In: A.B.R. Thomson and E.A. Shaffer (eds.): First Principles of Gastroenterology and Hepatology, CAPstone Academic Publishers Ltd. Pp 413-424,2 012.

Szilagyi, Andrew

-- Marton A, Xue X, **Szilagyi A**. Meta-analysis: The Diagnostic Accuracy of Lactose Breath Hydrogen or Lactose Tolerance Tests for Predicting the North European lactase polymorphism C/T – 13910, *Alimentary Pharmacol Therap* 2012; 35: 429-440.

-- Al Qahtani A, Holcroft C, Gordon PH, **Szilagyi A**. Clinical variables related to small bowel obstruction: comparison of patients with and without Crohn’s disease. *Gastroenterology Insights* 2012; volume 4:e14; 57-62. <http://www.pagepress.org/journals/index.php/gi>

-- Fung QM, **Szilagyi A**. Carbohydrate Elimination or Adaptation Diet for Symptoms of Intestinal Discomfort in IBD: Rationales for “Gibsons’ Conundrum”. *International J Inflamm* 2012. ID 493717.

-- AlHarbi A, Almadi M, **Szilagyi A**. Unusual Cause of Upper Gastrointestinal Bleeding. *Gastroenterology* 2012; 211, 412-3.

--Lee B, **Szilagyi A**. Lactose: Uses in Industry and Biomedical Importance. In Dietary Sugars: Chemistry, Analysis, Function and Effects (Food and Nutritional Components in Focus) Royal Chemistry Society Publishing, London; Edited by Victor R. Preedy, 2012-11-29. ISBN: 978-1-84973-492-9. DOI:10.1039/9781849734929-00806.

SECTION III - CONFIDENTIAL INFORMATION

- 1. Consulting activities:** None reported